New asthma injection shows promise in early trial
NCT ID NCT06441812
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tests a new drug called SHR-1703, given as multiple injections under the skin, for people with eosinophilic asthma. The goal is to see if it is safe and helps control asthma over the long term. About 200 adults will take part, and researchers will monitor side effects, lung function, and asthma flare-ups for up to 2 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-1703 injection
- What this could lead to
- If successful, this could provide a new treatment option to better control eosinophilic asthma and reduce flare-ups.
- What could go wrong
- This is an early-phase trial with only 200 participants, so results may not apply to everyone. Side effects are still being studied, and the drug may not improve asthma control significantly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC ASTHMA PATIENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China